ARWR vs. BHVN, FOLD, RARE, ACAD, PRGO, UTHR, SRPT, RDY, CTLT, and ROIV
Should you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Biohaven (BHVN), Amicus Therapeutics (FOLD), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.
Arrowhead Pharmaceuticals received 153 more outperform votes than Biohaven when rated by MarketBeat users. However, 65.43% of users gave Biohaven an outperform vote while only 65.26% of users gave Arrowhead Pharmaceuticals an outperform vote.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 4.5% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Biohaven has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Biohaven has a net margin of 0.00% compared to Biohaven's net margin of -163.32%. Biohaven's return on equity of -140.72% beat Arrowhead Pharmaceuticals' return on equity.
In the previous week, Arrowhead Pharmaceuticals had 2 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for Arrowhead Pharmaceuticals and 3 mentions for Biohaven. Arrowhead Pharmaceuticals' average media sentiment score of 1.41 beat Biohaven's score of 0.94 indicating that Biohaven is being referred to more favorably in the media.
Biohaven presently has a consensus target price of $51.63, indicating a potential upside of 36.07%. Arrowhead Pharmaceuticals has a consensus target price of $51.00, indicating a potential upside of 113.21%. Given Biohaven's higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Biohaven.
Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Biohaven. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Summary
Biohaven beats Arrowhead Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Arrowhead Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arrowhead Pharmaceuticals Competitors List
Related Companies and Tools
